Month: January 2024

RIDGEFIELD, Conn., Jan. 02, 2024 (GLOBE NEWSWIRE) — The Chefs’ Warehouse, Inc. (NASDAQ: CHEF) (the “Company”), a premier distributor of specialty food products in the United States, Middle East, and Canada, today announced that the Company will present at the 2024 ICR Conference in Orlando, FL on Monday, January 8, 2024. The presentation will begin at 8:30 a.m. ET. Investors and interested parties may listen to a webcast of the fireside chat by visiting the Company’s investor relations website at http://investors.chefswarehouse.com/. About The Chefs’ Warehouse The Chefs’ Warehouse, Inc. is a premier distributor of specialty food products in the United States, Canada and the Middle East focused on serving the specific needs of chefs who own and/or operate some of the nation’s leading menu-driven independent restaurants, fine dining...

REDWOOD CITY, Calif., Jan. 02, 2024 (GLOBE NEWSWIRE) — Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) in mast cell-driven diseases such as chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU), as well as lower to intermediate risk myelodysplastic syndromes (LR-MDS) and novel stem cell transplant conditioning regimens, today announced that it will effect a 1-for-10 reverse stock split of its issued and outstanding voting common stock that will become effective at 12:01 a.m. Eastern Time on Thursday, January 4, 2024. Jasper’s voting common stock will commence trading on a reverse stock split-adjusted basis at the opening of the market on Thursday, January 4, 2024. Following the reverse stock split,...

WALTHAM, Mass. and BOULDER, Colo., Jan. 02, 2024 (GLOBE NEWSWIRE) — Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced that Andrew Robbins, President and Chief Executive Officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 9, 2024 at 4:30 p.m. PT/7:30 p.m. ET. A live webcast will be available on the Investors & Media page of Cogent’s website at investors.cogentbio.com. A replay of the webcast will be available approximately two hours after the completion of the event and will be archived for up to 30 days. About Cogent Biosciences, Inc.Cogent Biosciences is a biotechnology company focused on developing precision therapies for genetically defined diseases. The most...

SEATTLE, Jan. 02, 2024 (GLOBE NEWSWIRE) — Accolade, Inc. (NASDAQ: ACCD) today announced that it will be presenting at the following upcoming investor conferences:42nd Annual J.P. Morgan Healthcare Conference in San Francisco on Thursday, January 11 at 7:30am PT 26th Annual Needham Growth Conference in New York on Thursday, January 18 at 3:00pm ETA webcast of these events will be available at ir.accolade.com and a replay will be available for 90 days. About Accolade, Inc. Accolade (Nasdaq: ACCD) is a Personalized Healthcare company that provides millions of people and their families with exceptional healthcare experiences so they can live their healthiest lives. Accolade’s employer, health plan, and consumer solutions combine virtual primary care and mental health, expert medical opinion, and best-in-class care navigation. These...

SEATTLE, Jan. 02, 2024 (GLOBE NEWSWIRE) — Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), today announced that Thijs Spoor, the Company’s Chief Executive Officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA, on Thursday, January 11, 2024, at 12 p.m. PT. Management will also participate at investor conferences alongside the J.P. Morgan Healthcare Conference in San Francisco. 42nd Annual J.P. Morgan Healthcare Conference – Company PresentationDate: Thursday, January 11, 2024Time: 12 p.m. PTLocation: The Westin St. Francis Hotel, San Francisco, CA (Elizabethan B) 7th Annual BFC Global HealthCare BD & Investment Conference – Panel, “Great Science, Great Challenges: Partnership with the Big Pharma” Moderator: Thijs SpoorPanelists: Executives from...

BOSTON and LONDON, Jan. 02, 2024 (GLOBE NEWSWIRE) — Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today announced that it closed a private placement financing with existing investors, Akari Chairman Dr. Ray Prudo and Director Samir R. Patel, M.D., on December 29, 2023, resulting in gross proceeds of approximately $2 million. In connection with the financing, Akari issued 947,868 unregistered American Depository Shares (“ADSs”), each representing 2,000 of the company’s ordinary shares, at a purchase price of $2.11 per ADS. Paulson Investment Company, LLC acted as the exclusive placement agent for this financing. The ADSs described above were offered and sold in a private placement under Section 4(a)(2) of the Securities Act of 1933,...

Presentation will highlight new data of GT-02287 in preclinical models of Parkinson’s disease BETHESDA, Md., Jan. 02, 2024 (GLOBE NEWSWIRE) — Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced that a late-breaking abstract with new data of GT-02287 in preclinical models of Parkinson’s disease has been accepted for a platform presentation at the 20th Annual WORLDSymposium™ being held February 4-9, 2024 in San Diego, CA. Details of the platform presentation are as follows: Title: GT-02287, a clinical stage GCase enhancer, displays neuroprotection and restores motor function in preclinical models of Parkinson’s disease following delayed administrationPresenter:...

CAMBRIDGE, Mass., Jan. 02, 2024 (GLOBE NEWSWIRE) — Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that Keith Gottesdiener, M.D., President and Chief Executive Officer of Prime Medicine, will present a corporate overview at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2024 at 2:15 p.m. PT (5:15 p.m. ET) in San Francisco, CA. A live audio webcast of the presentation will be available under “Events & Presentations” in the News & Events section of the Company’s website at www.primemedicine.com. A replay of the webcast will be available on the Prime Medicine website for 30 days following the presentation. About Prime MedicinePrime Medicine is a leading biotechnology company dedicated...

Extensive Clinical Network and Flexible Service Model to Meet Hiring Demands in Healthcare and Other Regulated Industries INDEPENDENCE, Ohio, Jan. 02, 2024 (GLOBE NEWSWIRE) — Sterling Check Corp. (NASDAQ: STER) (“Sterling”), a leading global provider of background screening and identity services, today announced that it has acquired Vault Workforce Screening (“Vault”), a leading U.S. clinic management platform. The acquisition brings a network of 17,000 clinics and a flexible service model to enhance Sterling’s existing drug and health services. This will enable Sterling to deliver additional market leading screening solutions for employers in healthcare, transportation, and other regulated industries where staffing challenges are most acute, decreasing time-to-hire and improving employee retention. As part of Sterling’s strategy...

BioJet device exceeded performance targets for delivery of collaborator AstraZeneca’s molecule in preclinical study SAN DIEGO, Jan. 02, 2024 (GLOBE NEWSWIRE) — Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced that its BioJet™ Systemic Oral Delivery Platform has met key performance milestones as part of its research collaboration with AstraZeneca. The BioJet platform is designed to use needle-free, liquid jet injection to deliver drug into the small intestine for systemic absorption. “In a preclinical study, we assessed the bioavailability of our collaborator’s molecule when delivered via our BioJet device in a porcine model, with comparison to subcutaneous administration. BioJet devices were administered endoscopically, which is typical in a porcine model,...